Patents by Inventor Jiuqiao Zhao

Jiuqiao Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-B7-H7 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20250136696
    Abstract: Disclosed are an anti-B7-H7 antibody or an antigen-binding fragment thereof, a preparation method therefor and the use thereof. The anti-B7-H7 antibody or antigen-binding fragment thereof of the present invention has high affinity and high biological activity for B7-H7, and can effectively block the binding of B7-H7 to a receptor CD28H thereof and the binding of B7-H7 to a receptor KIR3DL3 thereof; furthermore, the anti-B7-H7 antibody or antigen-binding fragment thereof only specifically binds to B7-H7 without cross-reacting with other member proteins of the B7 family, and has good stability; in addition, the anti-B7-H7 antibody or antigen-binding fragment thereof shows strong in vivo anti-tumor activity.
    Type: Application
    Filed: January 17, 2023
    Publication date: May 1, 2025
    Inventors: Xiaodong Wu, Yongqiang Wang, Xiaocheng Lv, Fei Chen, Xuemei Li, Jiuqiao Zhao, Yiping Rong
  • Antibodies binding CTLA-4 and uses thereof
    Patent number: 12240905
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: March 4, 2025
    Assignee: Harbour BioMed (Shanghai) Co., Ltd.
    Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
  • CCR8 ANTIBODY AND APPLICATION THEREOF
    Publication number: 20240228635
    Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.
    Type: Application
    Filed: August 27, 2021
    Publication date: July 11, 2024
    Applicant: B7 THERAPEUTICS INC.
    Inventors: Shuang LU, Yongqiang WANG, Xin GAN, Fei CHEN, Jinqiu HE, Xiaohui SHAO, Shaoping HU, Chuchu ZHAO, Jiuqiao ZHAO, Yiping RONG
  • CCR8 ANTIBODY AND APPLICATION THEREOF
    Publication number: 20240132603
    Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: April 25, 2024
    Applicant: HARBOUR BIOMED US, INC.
    Inventors: Shuang LU, Yongqiang WANG, Xin GAN, Fei CHEN, Jinqiu HE, Xiaohui SHAO, Shaoping HU, Chuchu ZHAO, Jiuqiao ZHAO, Yiping RONG
  • ANTIBODIES BINDING CTLA-4 AND USES THEREOF
    Publication number: 20220002414
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 6, 2022
    Applicant: Harbour BioMed (Shanghai) Co., Ltd.
    Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
  • Antibodies binding CTLA-4 and uses thereof
    Patent number: 11098122
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 24, 2021
    Assignee: HARBOUR BIOMED (SHANGHAI) CO., LTD.
    Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
  • ANTIBODIES BINDING CTLA-4 AND USES THEREOF
    Publication number: 20190202914
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Application
    Filed: December 19, 2018
    Publication date: July 4, 2019
    Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG
  • Cloning and characterization of genes encoding bradykinin B1 receptor homologues from five mammalian species
    Patent number: 6469150
    Abstract: The genes for bradykinin B1 receptor from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig have been cloned and characterized. In addition to the delineation of the nucleotide and amino acid sequences, methods for identifying modulators of bradykinin B1 receptor activity using these molecules is also described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: October 22, 2002
    Assignee: Pharmacopeia, Inc.
    Inventors: Robert Horlick, Jiuqiao Zhao, Robert Swanson, Maria Webb, Barbara Strohl